SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2026 / Volume: 10 Issue: 1

The Relationship between Vitamin D and Insulin Resistance in Patients with Metabolic Syndrome

Gülten Tarhan(SAĞLIK BAKANLIĞI)0000-0002-3828-3849
Ali Ugur Uslu0000-0002-7746-1783
Pages
—
Publication Date
2026-01-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, vitamin D deficiency may predict insulin resistance in the metabolic syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Vitamin D (25-[OH]D) deficiency is a common health problem.
📊
Key Findings & Data:Recently, it has been found to be associated with chronic diseases such as metabolic syndrome, cardiovascular diseases and Tip 2 diabetes mellitus.
💡
Conclusion & Impact:In addition, vitamin D deficiency may predict insulin resistance in the metabolic syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:insülin resistans · metabolic syndrome · vitamin d

Abstract

Purpose: Vitamin D (25-[OH]D) deficiency is a common health problem. Recently, it has been found to be associated with chronic diseases such as metabolic syndrome, cardiovascular diseases and Tip 2 diabetes mellitus. The study purposed to determine the relationship between vitamin D levels and IR and MetS. Materials and methods: Our study was a retrospective study including 52 MetS patients diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III criteria and 74 age- and sex-matched healthy subjects. Insulin resistance was defined using a HOMA-IR threshold of ≥2.5. The study population was divided into 4 groups according to insulin resistance. 31 patients with IR were included in group 1 (MetS IR+), 21 patients without IR were included in group 2, 22 healthy subjects with IR were included in group 3 and 52 healthy subjects without IR were included in group 4. Results: 25-(OH)D values were 17.3±9.1 ng/mL for patients with MetS and 25.5±11.9 ng/mL for patients among the control group (P<0.0001). Significant statistical differences were observed in terms of 25-(OH)D levels between 1st (MetS IR+), 2nd, 3rd, and 4th groups (16.9±9.4 ng/mL, 18.6±8.5 ng/mL, 25.8±15.2 ng/mL, 25.3±9.3 ng/mL, P=0.001). 25-(OH)D remained an independent MetS IR+ predictor (P=0.004) in MetS IR+ logistic regression analysis using several variables. Conclusion: This study suggests that vitamin D deficiency is important in the pathogenesis of MetS and IR. In addition, vitamin D deficiency may predict insulin resistance in the metabolic syndrome.

🔖

Cite This Article

Tarhan, G., Uslu, A. U. (2026). The Relationship between Vitamin D and Insulin Resistance in Patients with Metabolic Syndrome. Journal of Basic and Clinical Health Sciences, Volume: 10 Issue: 1. https://doi.org/10.30621/jbachs.1623952

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (38)

  1. Stroia CM, Ghitea TC, Vrânceanu M, et al. Relationship between vitamin D3 deficiency, metabolic syndrome and VDR, GC, and CYP2R1 gene polymorphisms. Nutrients. 2024;16(9):1272.
  2. Mutt SJ, Jokelainen J, Sebert S, et al. Vitamin D status and components of metabolic syndrome in older subjects from Northern Finland (latitude 65° North). Nutrients. 2019;11(6):1239.
  3. Brannon PM, Fleet JC. Vitamin D. Adv Nutr. 2011;2(4):365–367.
  4. Thoufeeq MH. Vitamin D: the best thing under the sun? Eurasian J Med. 2017;49(3):228.
  5. Infante M, Ricordi C, Sanchez J, et al. Influence of vitamin D on islet autoimmunity and beta-cell function in type 1 diabetes. Nutrients. 2019;11(9):2185.
  6. Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881–886.
  7. Uslu AU, Sekin Y, Tarhan G, et al. Evaluation of monocyte to high-density lipoprotein cholesterol ratio in the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost. 2018;24(5):828–833.
  8. Tekin T, Cicek B, Konyaligil N. Regulatory peptide nesfatin-1 and its relationship with metabolic syndrome. Eurasian J Med. 2019;51(3):280–284.
  9. Brede S, Serfling G, Klement J, et al. Clinical scenario of the metabolic syndrome. Visc Med. 2016;32(5):336–341.
  10. Swarup S, Zeltser R. Metabolic syndrome. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
  11. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752.
  12. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
  13. Vardeny O, Gupta DK, Claggett B, et al. Insulin resistance and incident heart failure. JACC Heart Fail 2013;1(6):531–536.
  14. Kumari R, Kumar S, Kant R. An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019;13(4):2409–2417.
  15. Monserrat-Mesquida M, Quetglas-Llabrés M, Capó X, et al. Metabolic syndrome is associated with oxidative stress and proinflammatory state. Antioxidants. 2020;9(3):236.
  16. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15(11):2775–2791.
  17. Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem. 2000;275(12):9047–9054.
  18. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. In: Comprehensive Physiology. Hoboken (NJ): John Wiley & Sons; 2013. p. 1–58.
  19. Gobato AO, Vasques ACJ, Zambon MP, et al. Metabolic syndrome and insulin resistance in obese adolescents. Rev Paul Pediatr. 2014;32(1):55–59.
  20. Adnan E, Rahman IA, Faridin HP. Relationship between insulin resistance, metabolic syndrome components and serum uric acid. Diabetes Metab Syndr. 2019;13(3):2158–2162.
  21. Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2010;39(2):419–446.
  22. Tai K, Need AG, Horowitz M, Chapman IM. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition. 2008;24(3):279–285.
  23. Barker T, Martins TB, Hill HR, et al. Circulating pro-inflammatory cytokines are elevated and peak power output correlates with 25-hydroxyvitamin D in vitamin D insufficient adults. Eur J Appl Physiol. 2013;113(6):1523–1534.
  24. Khoo AL, Chai LY, Koenen HJ, et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol. 2011;164(1):72–79.
  25. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–825.
  26. Forouhi NG, Luan J, Cooper A, et al. Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance. Diabetes. 2008;57(10):2619–2625.
  27. Maestro B, Campión J, Dávila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness. J Steroid Biochem Mol Biol. 2000;73(1–2):1–6.
  28. Sun G, Vasdev S, Martin GR, Gadag V, Zhang H. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005;54(11):3336–3339.
  29. Ahlström T, Hagström E, Larsson A, et al. Parathyroid hormone and calcium are related to cardiovascular risk factors and metabolic syndrome. Metabolism. 2009;58(10):1482–1487.
  30. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28(5):1228–1230.
  31. Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort. Diabetes Care. 2006;29(10):2244–2246.
  32. Esteghamati A, Aryan Z, Esteghamati AR, et al. Association of vitamin D deficiency with insulin resistance in non-diabetic subjects and type 2 diabetic patients. Diabetes Metab Syndr. 2015;9(4):273–277.
  33. Guasch A, Bulló M, Rabassa A, et al. Plasma vitamin D levels are associated with lipid metabolism in type 2 diabetes. Atherosclerosis. 2012;223(2):516–519.
  34. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72(3):690–693.
  35. Al-Dabhani K, Tsilidis KK, Murphy N, et al. Vitamin D deficiency and risk of metabolic syndrome: a meta-analysis. Eur J Clin Nutr. 2017;71(1):18–25.
  36. Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective association of 25-hydroxyvitamin D with metabolic syndrome. Diabetes Care. 2014;37(3):661–668.
  37. Mansouri M, Abasi R, Nasiri M, et al. Association of vitamin D deficiency with metabolic syndrome and obesity in adults. Nutr Metab Cardiovasc Dis. 2018;28(6):549–554.
  38. Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520–530.